Project Grant R41ES033857

Award Date 12/20/21
Completion Date 11/30/23
Dollars Obligated $767K
Federal Grant Program
93.113
Assistance Type
Project Grant
Place of Performance
Raleigh, NC 27614, USA
Similar Awards
This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...
This Project Grant award, provided by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program, supports the development of statistical methods for precision environmental health research focused on mixture exposures. The award, totaling $528,194 and effective from July 6, 2024 to April 30, 2029, will allow the principal investigator at Colorado State University to: Develop a general framework for estimating effect heterogeneity in...
This Project Grant award from the Environmental Protection Agency's Science to Achieve Results (STAR) Research Program (CFDA 66.509) provides $157,667 to Arizona State University (ASU) to develop new models, methods, and software tools for discovering and designing novel reaction networks and processes essential for transforming the U.S. chemicals industry toward greater sustainability and circularity. Key activities under this award include: 1) creating an open-access model of the current...
This $900,804 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) federal grant program supports the development and validation of an integrated microphysiological screening platform (MPS) with "virtual human" models to assess chemical toxicity. The key products and services to be delivered include: A 96-well MPS screening platform that combines elements of the awardee's commercial 48-well MPS with highly...
This Project Grant award from the National Science Foundation (CFDA 47.084, NSF Technology, Innovation, and Partnerships program) provides $264,736 to Duet Biosystems, Inc. to develop an AI-enabled toolkit for optimizing combination drug discovery and development. The project aims to leverage improvements in quantitative understanding of drug-drug synergy to overcome challenges associated with combination drug therapies, which are widely used to treat diseases like cancer, Alzheimer's, heart...
This $157,667 federal Project Grant awarded by the U.S. Environmental Protection Agency (EPA) under the Science to Achieve Results (STAR) Research Program aims to develop a predicted reaction network using experimental and computational data to describe the environmental lifecycle of persistent biological transformation products (TPs) of chemicals. The project will integrate new approach methodologies and supplement experimental data with computational techniques to select critical and stable...
This Project Grant award from the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program provides $275,956 to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimizations of their dosing. The project aims to create a generalized, self-dose-optimizing multi-sensor-integrated multi-organ-on-a-chip...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $999,878 to Akttyva Therapeutics, Inc., a small business located in Watertown, MA, to develop an AI-assisted drug discovery platform to identify existing drugs and new chemical entities capable of repairing vascular permeability barriers. The project aims to address unmet clinical needs for conditions like acute respiratory distress...
This Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $295,734 to Litron Laboratories Ltd, a for-profit biotechnology company, to develop a comprehensive hen's egg model for genotoxicity testing. The project aims to create a non-animal, metabolically-active in vitro system that can effectively assess the genotoxic risk of pharmaceuticals and industrial chemicals. Key deliverables include...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $419,011 to Emory University to develop innovative dimensionality reduction techniques for assessing the joint health effects of air pollution mixtures. The research aims to advance causal modeling approaches that preserve the relationships between air pollutants and health outcomes, in order to provide more accurate assessments of the public...

ARTIFICIAL INTELLIGENCE TOOLKIT FOR PREDICTING MIXTURE TOXICITY - CHEMICAL SAFETY ASSESSMENT IS TYPICALLY CONDUCTED FOR INDIVIDUAL CHEMICALS. HOWEVER, INDUSTRIAL CHEMICALS RARELY ACT IN ISOLATION TO PRODUCE ADVERSE EFFECTS, SO MIXTURE TOXICITY ASSESSMENT REPRESENTS A COMPLEX BUT MORE REALISTIC APPROACH TO ALLEVIATING ENVIRONMENTAL CHEMICAL SAFETY CONCERNS. THERE IS AN EXCITING AND HIGHLY IMPACTFUL CHALLENGE TO DEVELOP INNOVATIVE APPROACHES EMPLOYING MODERN AI ALGORITHMS TO PROVIDE ACCURATE TOXICITY PREDICTION OF MIXTURES FROM THEIR CHEMICAL COMPOSITION, INCLUDING THE ASSESSMENT OF SYNERGISTIC EFFECTS. WE RECENTLY FORMED PREDICTIVE, LLC, TO ENABLE THE DEVELOPMENT AND DISTRIBUTION OF COMMERCIAL AND REGULATORY STRENGTH MODELS TO PREDICT IMPORTANT TOXICITY ENDPOINTS. IN THIS PHASE I STTR APPLICATION, WE PROPOSE TO ESTABLISH A NOVEL WEB BASED PREMIXT (PREDICTOR OF MIXTURE TOXICITY) TOOLKIT BUILT ON BEST PRACTICES FOR (I) DATA COLLECTION, CLEANING, HARMONIZATION, AND INTEGRATION, (II) MODEL DEVELOPMENT USING CURRENT AND EMERGING AI APPROACHES AND THOUGHTFUL STRATEGIES OF PROSPECTIVE VALIDATION OF MIXTURE MODELS, AND (III) PREDICTION OF SPECIFIC ENDPOINT TOXICITIES FOR BOTH PURE CHEMICALS AND MIXTURES. WE WILL ACHIEVE THIS OBJECTIVE BY FOCUSING ON THE FOLLOWING SPECIFIC AIMS. SPECIFIC AIM 1: COLLECT, CURATE, AND INTEGRATE THE LARGEST PUBLICLY AVAILABLE MIXTURE TOXICITY DATASETS. WE WILL EXPLORE ALL THE PUBLICLY ACCESSIBLE DATA ON MIXTURE TOXICITY. INITIAL DATASETS WILL INCLUDE ACUTE ORAL TOXICITY, ACUTE INHALATION TOXICITY, ACUTE DERMAL TOXICITY, SKIN SENSITIZATION, SKIN IRRITATION AND CORROSION, AND EYE IRRITATION AND CORROSION ENDPOINTS (COLLECTIVELY KNOWN AS "6-PACK") AS WELL AS PESTICIDES. WE WILL ALSO COLLECT AND CURATE DATASETS OF UNTESTED CHEMICALS AND MIXTURES OF THE ENVIRONMENTAL CONCERN WITH KNOWN COMPOSITION SUCH AS HIGH PRODUCTION VOLUME (HPV) CHEMICALS AND REGISTERED SUBSTANCES IN THE REACH DATABASE. THE DATA WILL BE (RE)STRUCTURED, HARMONIZED, AND PREPARED FOR CHEMINFORMATICS ANALYSIS FOLLOWING CUSTOM PROCEDURES. SPECIFIC AIM 2: DEVELOP AI MODELS OF MIXTURE TOXICITY. USING DATA PREPARED IN AIM 1, WE WILL DEVELOP RIGOROUSLY VALIDATED MODELS OF SEVERAL SELECTED ENDPOINT MIXTURE TOXICITIES OF RELEVANCE TO ENVIRONMENTAL HEALTH RISK ASSESSMENT. WE WILL EMPLOY TWO TYPES OF MIXTURE-SPECIFIC DESCRIPTORS: SIMPLEX REPRESENTATION OF MOLECULAR STRUCTURE (SIRMS) AND MIXTURE GRAPH CONVOLUTION DESCRIPTORS. MODELING APPROACHES WILL INCLUDE BOTH COMMON (E.G., RANDOM FOREST) AS WELL AS INNOVATIVE GRAPH CONVOLUTIONAL NETWORKS (GCN) APPROACHES. SPECIFIC AIM 3. DEVELOP THE PREMIXT TOOLKIT AND PORTAL SUPPORTING THE TOXICITY PREDICTION OF CHEMICALS AND THEIR MIXTURES. WE WILL INTEGRATE CURATED DATA AND VALIDATED MODELS INTO THE PREMIXT WEB APPLICATION. THIS PREMIXT SERVER WILL BE ABLE TO PREDICT MIXTURE TOXICITY, INCLUDING POSSIBLE SYNERGY OF MIXTURE COMPONENTS, BASED ON THE KNOWLEDGE OF CHEMICALS FOUND AND CHARACTERIZED IN THE MIXTURE. SUCCESSFUL COMPLETION OF OUR PHASE I STUDIES WILL RESULT IN THE DEVELOPMENT OF THE PREMIXT WEB APPLICATION AS A CENTRALIZED RESOURCE TO EVALUATE MIXTURE TOXICITY, INCLUDING THE SYNERGY BETWEEN MIXTURE COMPONENTS.

Posted 12/20/21, 12:00 AM